Scholar Rock Holding Corporation (SRRK)
Company Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.
The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2012 |
| IPO Date | May 24, 2018 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 145 |
| CEO | Nagesh Mahanthappa |
Contact Details
Address:
620 Memorial Dr Fl 2 Cambridge, Massachusetts 02139-4815 United States | |
| Phone | 857 259 3860 |
| Website | scholarrock.com |
Stock Details
| Ticker Symbol | SRRK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001727196 |
| CUSIP Number | 80706P103 |
| ISIN Number | US80706P1030 |
| Employer ID | 82-3750435 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nagesh K. Mahanthappa MBA, Ph.D. | Interim Chief Executive Officer, President and Director |
| Edward H. Myles M.B.A., MBA | Chief Financial Officer, Chief Operating Officer and Treasurer |
| Dr. Gregory John Carven Ph.D. | Chief Scientific Officer |
| Catherine Hu | Vice President of Investor Relations and Corporate Communications |
| Junlin Ho J.D. | General Counsel and Corporate Secretary |
| Caryn Parlavecchio | Chief Human Resources Officer |
| Lisa Amaya Price | Senior Vice President of Human Resources |
| Dr. George G. Nomikos M.D., Ph.D. | Senior Vice President of Medical and Clinical Sciences and Head of Muscle Therapeutic Area |
| Erin Moore | Senior Vice President of Finance |
| Ryan Iarrobino | Senior Vice President of Clinical Development and Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Jun 24, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 24, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Jun 24, 2022 | 3 | Initial statement of beneficial ownership of securities |
| Jun 21, 2022 | 8-K | Current report |
| Jun 21, 2022 | 424B5 | Prospectus [Rule 424(b)(5)] |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 21, 2022 | 4 | Statement of changes in beneficial ownership of securities |